Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.
CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.
Clonality:
Monoclonal
Clone Designation:
[121SLE]
UniProt:
Not Known
Purity:
PEG precipitation
Form:
1 mg/ml in 1X PBS, BSA free, sodium azide free
Antibody Type:
Primary Antibody
Application Dilute:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Application Notes:
Optimal dilution of the CA19-9 antibody should be determined by the researcher.1. No special pretreatment is required for the immunohistochemical staining of formalin-fixed, paraffin-embedded tissues2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
